Cholestatic liver diseases: new targets, new therapies

Priscila Santiago, Andrew R. Scheinberg, Cynthia Levy

Research output: Contribution to journalReview articlepeer-review

34 Scopus citations


Cholestatic liver diseases result from gradual destruction of bile ducts, accumulation of bile acids and self-perpetuation of the inflammatory process leading to damage to cholangiocytes and hepatocytes. If left untreated, cholestasis will lead to fibrosis, biliary cirrhosis, and ultimately end-stage liver disease. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are the two most common chronic cholestatic liver diseases affecting adults, and their etiologies remain puzzling. While treatment with ursodeoxycholic acid (UDCA) has significantly improved outcomes and prolonged transplant-free survival for patients with PBC, treatment options for UDCA nonresponders remain limited. Furthermore, there is no available medical therapy for PSC. With recent advances in molecular biochemistry specifically related to bile acid regulation and understanding of immunologic pathways, novel pharmacologic treatments have emerged. In this review, we discuss the standard of care and emphasize the various emerging treatments for PBC and PSC.

Original languageEnglish (US)
JournalTherapeutic Advances in Gastroenterology
StatePublished - Jan 1 2018


  • FXR agonists
  • bile acids
  • cholestatic liver diseases
  • fibrates
  • primary biliary cholangitis
  • primary sclerosing cholangitis

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Cholestatic liver diseases: new targets, new therapies'. Together they form a unique fingerprint.

Cite this